Premium
Lymph node involvement: Positive about the role of the recurrence score in estrogen‐driven breast cancer?
Author(s) -
Kalinsky Kevin,
O’Regan Ruth M.
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31814
Subject(s) - medicine , breast cancer , observational study , oncology , lymph node , chemotherapy , randomized controlled trial , estrogen , clinical trial , population , cancer , environmental health
It remains unclear whether there is clinical utility for withholding chemotherapy in HR+/HER2‐, node‐positive breast cancer based upon the 21‐gene Recurrence Score. While we await the results from randomized, phase III trials, this editorial addresses additional observational data that suggest there may be a role for this genomic assay in this patient population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom